Ross A Abrams1, Kathryn A Winter2, Howard Safran3, Karyn A Goodman4, William F Regine5, Adam C Berger6, Michael T Gillin7, Philip A Philip8, Andrew M Lowy9, Abraham Wu10, Thomas A DiPetrillo1, Benjamin W Corn11, Samantha A Seaward12, Michael G Haddock13, Suisui Song14, Yixing Jiang5, Barbara J Fisher15, Alan W Katz16, Sharmila Mehta17, Christopher G Willett18, Christopher H Crane10. 1. Rush University Medical Center, Chicago, IL. 2. NRG Oncology Statistics and Data Management Center. 3. Rhode Island Hospital. 4. University of Colorado Cancer Center, Denver, CO. 5. University of Maryland/Greenebaum Cancer Center, Baltimore, MD. 6. Thomas Jefferson University Hospital, Philadelphia, PA. 7. MD Anderson Cancer Center, Houston, TX. 8. Wayne State University/Karmanos Cancer Institute, Detroit, MI. 9. UC San Diego Moores Cancer Center, San Diego. 10. Memorial Sloan Kettering Cancer, New York. 11. Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 12. Department of Radiation Oncology; Kaiser Permanente East Bay Cancer Center, Oakland, CA. 13. Mayo Clinic, Rochester, MN. 14. USC/Norris Comprehensive Cancer Center, Los Angeles, CA. 15. London Regional Cancer Program, London, ON, Canada. 16. University of Rochester, Rochester, NY. 17. Spartanburg Regional Medical Center, Spartanburg, SC. 18. Duke University Medical Center, Durham, NC.
Abstract
PURPOSE: NRG/RTOG 0848 was designed to determine whether adjuvant radiation with fluoropyrimidine sensitization improved survival following gemcitabine-based adjuvant chemotherapy for patients with resected pancreatic head adenocarcinoma. In step 1 of this protocol, patients were randomized to adjuvant gemcitabine versus the combination of gemcitabine and erlotinib. This manuscript reports the final analysis of these step 1 data. METHODS: Eligibility-within 10 weeks of curative intent pancreaticoduodenectomy with postoperative CA19-9<180. Gemcitabine arm-6 cycles of gemcitabine. Gemcitabine+erlotinib arm-gemcitabine and erlotinib 100 mg/d. Two hundred deaths provided 90% power (1-sided α=0.15) to detect the hypothesized OS signal (hazard ratio=0.72) in favor of the arm 2. RESULTS: From November 17, 2009 to February 28, 2014, 163 patients were randomized and evaluable for arm 1 and 159 for arm 2. Median age was 63 (39 to 86) years. CA19-9 ≤90 in 93%. Arm 1: 32 patients (20%) grade 4 and 2 (1%) grade 5 adverse events; arm 2, 27 (17%) grade 4 and 3 (2%) grade 5. GI adverse events, arm 1: 22% grade ≥3 and arm 2: 28%, (P=0.22). The median follow-up (surviving patients) was 42.5 months (min-max: <1 to 75). With 203 deaths, the median and 3-year OS (95% confidence interval) are 29.9 months (21.7, 33.4) and 39% (30, 45) for arm 1 and 28.1 months (20.7, 30.9) and 39% (31, 47) for arm 2 (log-rank P=0.62). Hazard ratio (95% confidence interval) comparing OS of arm 2 to arm 1 is 1.04 (0.79, 1.38). CONCLUSIONS: The addition of adjuvant erlotinib to gemcitabine did not provide a signal for increased OS in this trial.
PURPOSE: NRG/RTOG 0848 was designed to determine whether adjuvant radiation with fluoropyrimidine sensitization improved survival following gemcitabine-based adjuvant chemotherapy for patients with resected pancreatic head adenocarcinoma. In step 1 of this protocol, patients were randomized to adjuvant gemcitabine versus the combination of gemcitabine and erlotinib. This manuscript reports the final analysis of these step 1 data. METHODS: Eligibility-within 10 weeks of curative intent pancreaticoduodenectomy with postoperative CA19-9<180. Gemcitabine arm-6 cycles of gemcitabine. Gemcitabine+erlotinib arm-gemcitabine and erlotinib 100 mg/d. Two hundred deaths provided 90% power (1-sided α=0.15) to detect the hypothesized OS signal (hazard ratio=0.72) in favor of the arm 2. RESULTS: From November 17, 2009 to February 28, 2014, 163 patients were randomized and evaluable for arm 1 and 159 for arm 2. Median age was 63 (39 to 86) years. CA19-9 ≤90 in 93%. Arm 1: 32 patients (20%) grade 4 and 2 (1%) grade 5 adverse events; arm 2, 27 (17%) grade 4 and 3 (2%) grade 5. GI adverse events, arm 1: 22% grade ≥3 and arm 2: 28%, (P=0.22). The median follow-up (surviving patients) was 42.5 months (min-max: <1 to 75). With 203 deaths, the median and 3-year OS (95% confidence interval) are 29.9 months (21.7, 33.4) and 39% (30, 45) for arm 1 and 28.1 months (20.7, 30.9) and 39% (31, 47) for arm 2 (log-rank P=0.62). Hazard ratio (95% confidence interval) comparing OS of arm 2 to arm 1 is 1.04 (0.79, 1.38). CONCLUSIONS: The addition of adjuvant erlotinib to gemcitabine did not provide a signal for increased OS in this trial.
Authors: J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils Journal: Ann Surg Date: 1999-12 Impact factor: 12.969
Authors: Adam C Berger; Kathryn Winter; John P Hoffman; William F Regine; Ross A Abrams; Howard Safran; Gary M Freedman; Alan B Benson; John Macdonald; Christopher G Willett Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-09 Impact factor: 7.038
Authors: John P Neoptolemos; Daniel H Palmer; Paula Ghaneh; Eftychia E Psarelli; Juan W Valle; Christopher M Halloran; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting Ma; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Thilo Hackert; Richard Jackson; Markus W Büchler Journal: Lancet Date: 2017-01-25 Impact factor: 79.321
Authors: Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar Journal: J Clin Oncol Date: 2007-04-23 Impact factor: 44.544
Authors: John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler Journal: N Engl J Med Date: 2004-03-18 Impact factor: 91.245
Authors: Adam C Berger; Miguel Garcia; John P Hoffman; William F Regine; Ross A Abrams; Howard Safran; Andre Konski; Alan B Benson; John MacDonald; Christopher G Willett Journal: J Clin Oncol Date: 2008-11-24 Impact factor: 44.544
Authors: Mark B Ulanja; Alastair E Moody; Bryce D Beutler; Daniel Antwi-Amoabeng; Ganiyu A Rahman; Olatunji B Alese Journal: Oncotarget Date: 2022-06-15
Authors: Aaron J Grossberg; Linda C Chu; Christopher R Deig; Eliot K Fishman; William L Hwang; Anirban Maitra; Daniel L Marks; Arnav Mehta; Nima Nabavizadeh; Diane M Simeone; Colin D Weekes; Charles R Thomas Journal: CA Cancer J Clin Date: 2020-07-19 Impact factor: 508.702